Chest
Clinical InvestigationsCOPDThe Impact of Combined Inhaled Bronchodilator Therapy in the Treatment of COPD
Section snippets
Source of Data
The computerized prescription and hospitalization databases of, Saskatchewan, developed as a result of the universal health insuranceprogram provided to residents of this Canadian province, constitutedthe primary source of data for this study.111213 All Saskatchewan residents (> 1 million) are eligible for coverage, withthe exception of registered Indians, members of the Armed Forces, the, Royal Canadian Mounted Police, and veterans. These exceptions represent< 5% of the population.
Demographic
Results
Among the 1,052 subjects newly treated with two differentbronchodilators, 641 subjects initiated drug therapy with the combinedinhaled bronchodilator (combined inhaled bronchodilator group) and 411subjects were dispensed, on the same day, ipratropium bromide andinhaled β2-agonist in two separate canisters(double-users group). Table 1 presentsthe sociodemographic characteristics at cohort entry. Patientsinitiated on combined inhaled bronchodilator therapy included fewerwomen and were less likely
Discussion
We conducted a study, in the context of actual medical practice, to determine the impact of the inclusion in the Saskatchewan drugformulary of a combination product hypothesized to improve patientcompliance. We found that the introduction of combined inhaledbronchodilator therapy did not significantly alter patterns of use ofbronchodilators, other respiratory drugs, and antibiotics.
The first important result of this study is that the subjects initiatedon combined inhaled bronchodilator therapy
References (21)
Multiple dose regimens: impact on compliance
Chest
(1995)- et al.
Medication adherence patterns in chronic obstructive pulmonary disease
Chest
(1991) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(1995)In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial
Chest
(1994)- et al.
Effective site of bronchodilation by β-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter
Am Rev Respir Dis
(1992) The background to Duovent
Postgrad Med J
(1984)- et al.
Health promotion and maintenance for patients with chronic obstructive pulmonary disease: a review
J Chronic Dis
(1980) - et al.
Patient compliance: are we wasting our time and don't know it?
Am Rev Respir Dis
(1992) Saskatchewan Health Drug Plan Formulary, 45th ed
(1996)
Cited by (27)
Cost-Effectiveness and Impact on Health Care Utilization of Interventions to Improve Medication Adherence and Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review
2024, Journal of Allergy and Clinical Immunology: In PracticeSymptom variability and control in COPD: Advantages of dual bronchodilation therapy
2017, Respiratory MedicineCitation Excerpt :An increase in the dose of bronchodilator in accordance with its pharmacological characteristics [1,2,47–50]. The addition of a second long-acting bronchodilator with a different mechanism of action [1,2,44,51–59]. The addition of ICS, in patients with frequent exacerbations [1,2,55,60–62].
Effect of oxygen-driven nebulization at different oxygen flows in acute exacerbation of chronic obstructive pulmonary disease patients
2014, American Journal of the Medical SciencesCitation Excerpt :All patients were seated while inhaling aerosol by a mouthpiece. Patients should gargle and expectoration each time after nebulization to avoid adverse reaction.21–23 ODN was performed 2-3 times a day.
Long-term pharmacologic management of patients with chronic obstructive pulmonary disease
2004, Clinical Cornerstone
This study was supported through a grant from Boehringer Ingelheim Canada Ltd. Serge Benayoun was the recipient of a research fellowshipfrom the Fonds de la Recherche en Santé du Québec for theperiod of this research. Samy Suissa is a Senior Scientist of the, Medical Research Council of Canada. The Pharmacoepidemiology Research Unit is funded by an équipe grant from the Fonds de la Rechercheen Santé du Québec. This study was designed, conducted, analyzed, and interpreted independently of the sponsor.
This study is based in part on data provided by the, Saskatchewan Department of Health. The interpretation and conclusionscontained herein do not necessarily represent those of the governmentof Saskatchewan or the Saskatchewan Department of Health.